A Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of PRA023 in participants with
moderately to severely active Ulcerative Colitis.
The purpose of Cohort 2 of the study is to assess the safety and efficacy of PRA023 in
participants with moderately to severely active ulcerative colitis who are companion
diagnostic positive.
After the completion of the 12-week induction, all participants have the option to continue
in the open-label extension for another 38 weeks.